More recently, the combination of nimotuzumab with melatonin, which is known to disrupt EGFR in its intracellular segment, demonstrated increased cytotoxicity and apoptosis of cancer cells in vitro and in xenograft mouse glioblastoma models [132]. The gene discussed is EGFR; the disease is glioblastoma.